Ipsen’s elafibranor recommended for use in patients with rare liver disease

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This makes elafibranor the first medicine for PBC approved for use on the NHS in nearly a decade.

How Many Kids Use Melatonin?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

November 19, 2023

Before Stroke Thrombectomy, Keep the Bed Flat, Trial Says

PHOENIX — For large vessel occlusion (LVO) acute ischemic stroke patients planned for mechanical thrombectomy, bed positioning made a big difference in clinical worsening, the

February 8, 2024

Study links sleep disorders to higher healthcare use in chronically ill children

The risk of increased health care utilization among children with a chronic medical condition is higher for those who also have a sleep disorder, according

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.